✉news HealthMedicine first seen 7 d ago, last 7 d ago, peak #37
Bispecific ADC doubles progression-free survival in breast cancer
Original: ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer
Data presented at the ESMO 2026 congress show an $8.4 billion bispecific antibody-drug conjugate doubled progression-free survival in patients with HR-positive, HER2-negative breast cancer. The results point to a significant advance for a common cancer subtype with limited options after endocrine therapy resistance, and are drawing attention from oncologists and investors alike given the drug's commercial potential.
Why now: New ESMO congress data showing doubled progression-free survival represent a major clinical advance in a common breast cancer subtype.
ESMObispecific ADCHR+/HER2- breast cancer
Rank over time, top of the chart is #1. 2 snapshots from 7 d ago to 7 d ago.
Evidence
- ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer · Clinical Trials Arena
API: https://socialmediatrends-api.osmike.com/v1/trends/3671690